Biohit Oyj

Board/Management Information • Jul 30, 2018

Disclosure 363469

Biohit Oyj - Changes board/management/auditors

Changes to Biohit Oyj’s management

Adjunct professor (molecular mircobiology) and computer science engineer Minna Mäki (b. 1969) has been appointed R&D and production director and as a member of the Management Team of Biohit Oyj starting July 30th 2018. Mäki will report to CEO Semi Korpela.

Mäki joins Biohit Oyj from Orion Diagnostica Oyj where she worked at the R&D department with the Orion GenRead product family. She also worked as a work package manager for the national research program Personalized diagnostics and care. Previously, Mäki has worked at Mobidiag Oy as R&D director and as a researcher at the University of Helsinki.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit Oyj in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission ‘Innovating for Health’ means that we provide innovative products and services to promote research and early diagnostics. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares (BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare. www.biohithealthcare.com